Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

BACKGROUND. We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months 0 and 12 (2D_M0,12) in girls aged 9–14 years compared with a 3-dose schedule at months 0, 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Li-Min, Puthanakit, Thanyawee, Cheng-Hsun, Chiu, Ren-Bin, Tang, Schwarz, Tino, Pellegrino, Angelo, Esposito, Susanna, Frenette, Louise, McNeil, Shelly, Durando, Paolo, Rheault, Paul, Giaquinto, Carlo, Horn, Michael, Petry, Karl Ulrich, Peters, Klaus, Azhar, Toma, Hillemanns, Peter, De Simoni, Stephanie, Friel, Damien, Pemmaraju, Suryakiran, Hezareh, Marjan, Thomas, Florence, Descamps, Dominique, Folschweiller, Nicolas, Struyf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853959/
https://www.ncbi.nlm.nih.gov/pubmed/28591778
http://dx.doi.org/10.1093/infdis/jix154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853959/
https://www.ncbi.nlm.nih.gov/pubmed/28591778
http://dx.doi.org/10.1093/infdis/jix154

Ejemplares similares